Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol

Clinical Transplantation

Volumn 21, Issue 4, 2007, Pages 532-535

  Pelletier, Ronald P ^a,b   Soule, J ^a   Henry, M L ^a   Rajab, A ^a   Ferguson, R M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Clinical outcomes; Drug toxicity; Kidney transplantation; Mycophenolic acid; Nephrotoxicity

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SIROLIMUS; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 34547454385     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00685.x     Document Type: Article

References (13)

1. H alloran P, M athew T, T omlanovich S, G roth C, H ooftman L, B arker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997: 63: 39.
2. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
3. Meier-Kriesche H, Ojo A, Arndorfer J et al. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Transplant Proc 2001: 2: 1005.
4. Borrows R CG, Loucaidou M, James A et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity. Am J Transplant 2006: 6: 121.
5. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004: 4: 1079.
6. Le Meur YBM, Lavaud S, Etienne I et al. Concentration controlled versus fixed dose of MMF in kidney transplant recipients: Preliminary results of a French multicenter randomized study. Am J Transplant 2005: 11: 242.
7. Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
8. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005: 19: 779.
9. H ardinger KL, B rennan DC, L owell J, S chnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004: 17: 609. Epub 2004 Oct 20-29.
10. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003: 17: 200.
11. Meier-Kriesche HU, Chu AH, David KM, Chi-Burris K, Steffen BJ. Switching immunosuppression medications after renal transplantation-a common practice. Nephrol Dial Transplant 2006: 21: 2256. Epub 2006 Mar 22-30.
12. Pallet N, Anglicheau D, Martinez F, Mamzer MF, Legendre C, Thervet E. Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor. Transplantation 2006: 81: 949.
13. Knoll G, Mac Donald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrology 2003: 14: 2381.